REFERENCES
- Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795.
- Hedegaard H, Chen LH, Warner M. Drug-Poisoning Deaths Involving Heroin: United States, 2000–2013. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2015. NCHS Data Brief No. 190. Available at: http://www.cdc.gov/nchs/data/databriefs/db190.htm.
- Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. HHS Publication No. (SMA) 13-4760, DAWN Series D-39.
- Hedegaard H, Chen LH, Warner M. Drug- poisoning deaths involving heroin: United States, 2000–2013. NCHS data brief, no 190. Hyattsville, MD: National Center for Health Statistics. 2015.
- 2013 Drug Overdose Mortality Data Announced. Available at: http://www.whitehouse.gov/ondcp/news-releases/2013-mortality-data. Accessed January 12, 2015.
- The White House News Releases. 2013 Drug Overdose Mortality Data Announced. Available at: https://www.whitehouse.gov/blog/2014/06/19/white-house-summit-opioid-epidemic.
- Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066.
- Lynch, FL, McCarty D, Mertens J, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014;9(1):16.
- Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235–S248.
- Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104:982–992.
- Clark RE, Samnaliev M, Baxter JD, Leung GY. Addiction treatment with buprenorphine. The evidence doesn't justify steps by state Medicaid programs to restrict opioid. Health Aff. 2011;30:1425–1433. doi: 10.1377/hlthaff.2010.0532.
- Hatch OG, Markey EJ, Ayotte KA, et al. Personal Communication. Available at: http://www.markey.senate.gov/imo/media/doc/2015-08-10-SecBurwell-HHS-buprenorphine.pdf. Accessed September 11, 2015.
- The Drug Addiction Treatment Act of 2000 (H.R. 4365, Title XXXV). Available at: https://www.congress.gov/bill/106th-congress/house-bill/4365. Accessed August 27, 2015.
- Jones CM, Campopiano M, Baldwin, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–e63.
- Young A, Chaudhry HJ, Pei X, Halbesleben K, Polk DH, Dugan M. A census of actively licensed physicians in the United States, 2014. J Med Regul. 2015;101:8–23. Available online from the Federation of State Medical Boards at: http://www.fsmb.org/Media/Default/PDF/Census/2014census.pdf.
- Centers for Disease Control and Prevention. New research reveals the trends and risk factors behind America's growing heroin epidemic. Press release dated July 7, 2015. Available at: http://www.cdc.gov/media/releases/2015/p0707-heroin-epidemic.html. Accessed August 28, 2015.
- Naegle MA. Nursing care in alcohol and drug user treatment facilities. Substance Use & Misuse. 2015;50 (8-9):1153–8.
- Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015;48:104–111.
- Dick AW, Pacula RL, Gordon AJ, et al. Increasing access to opioid agonist treatment in US treatment shortage areas. Health Aff. 2015;34:1028–1034.
- Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed for treating opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93:561–583.
- Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. Subst Abus. 2015. In press. doi: 10.1080/08897077.2015.1080208
- Stein BD, Gordon AJ, Dick AW. Buprenorphine waivers: the authors reply. Health Aff. 2015;34:1428.
- Murphy SM, Fishman PA, McPherson S, Dyck DG, Roll JR. Determinants of buprenorphine treatment for opioid dependence. J Subst Abuse Treat. 2014;46:315–319.
- Committee on the Robert Wood Johnson Foundation Initiative on the Future of Nursing, Institute of Medicine. The Future of Nursing: Leading Change, Advancing Health. Washington, DC: National Academies Press; 2011.
- American Association of Nurse Practitioners. State practice environment: States categorized by type. http://www.aanp.org/legislation-regulation/state-legislation/state-practice-environment/66-legislation-regulation/state-practice-environment/1380-state-practice-by-type. Accessed September 10, 2015.
- Oliva E, Trafton J, Harris AHS, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39:103–107.
- American Association of Nurse Practitioners. Fact sheet. Available at: http://www.aanp.org/all-about-nps/np-fact-sheet. Accessed August 28, 2015.
- APRN Prescribing Law: A State-by-State Summary. Medscape. July 25, 2013. Available at: http://www.medscape.com/viewarticle/440315. Accessed September 11, 2015.
- Newhouse RP, Stanik Hutt J, White KM, et al. Advanced practice nurse outcomes 1990–2008: a systematic review. Nurs Econ. 2011;29:230–250.
- Finnell DA, Allen KM. American Nurses Association, International Nurses Society on Addictions. Addictions Nursing: Scope and Standards of Practice. Silver Spring, MD: American Nurses Association; 2013.
- Center for Substance Abuse Treatment. Buprenorphine: A Guide for Nurses. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009. DHHS Publication No. (SMA) 09-4376.
- Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171:425–431.
- Strobbe S, Mathias L, Gibbons PW, Humenay E, Brower KJ. Buprenorphine clinic for opioid maintenance therapy: program description, process measures, and patient satisfaction. J Addict Nurs. 2011; 22:8–12.
- Roose RJ, Kunins HV, Sohler NL, Elam RT, Cunningham CO. Nurse practitioner and physician assistant interest in prescribing buprenorphine. J Subst Abuse Treat. 2008;34:456–459.
- Gordon AJ, Lo-Ciganic W, Cochran G, et al. Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program. J Addict Med. 2015. 2015 Dec;9(6):470-7. doi: 10.1097/ADM.0000000000000164.
- US Department of Health and Human Services. HHS takes strong steps to address opioid-drug related overdose, death and dependence. Available at: http://www.hhs.gov/news/press/2015pres/03/20150326a.html Accessed March 26, 2015.
- Strobbe S, Hobbins D. The prescribing of buprenorphine by advance practice addictions nurses. J Addict Nurs. 2012;23:82–83. Available at: http://www.intnsa.org/resources/publications/position_june_2012.pdf. Accessed August 27, 2015.
- The American Psychiatric Nurses Association. APNA Supports the Expansion of APRN Prescriptive Authority to Include Prescription of Buprenorphine and Buprenorphine/Naloxone (Suboxone). Released July 2, 2013. Available at: http://www.apna.org/i4a/pages/index.cfm?pageID=5513. Accessed August 27, 2015.
- AMERSA Web site. Available at: http://www.amersa.org/MisStat.asp.